Zomedica Q1 revenue $6.5M (+4% YoY), net loss $63.8M on $55.8M impairment

Zomedica Corp.

2025-Q1 EPS reported -$0.07 revenue$6,500,000

Revenue $6.5M (+4% YoY); gross margin 68% vs 66% in Q1 2024.
Net loss $63.8M includes $55.8M non-cash impairment from share price decline.
Adjusted EBITDA loss $5.7M vs $5.3M in Q1 2024; cash & securities $64.6M.
Consumables revenue up 13% to $4.5M; Diagnostics down 25% to $0.6M.
Shares outstanding 979.9M; liquidity down from $71.4M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.